Picard Medical reports financial growth and product innovation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Picard Medical Inc's stock fell 5.00% as it crossed below the 5-day SMA amid broader market gains.
The company reported a total revenue of $4.9 million for 2025, a 12.5% increase, driven by strong product demand in cardiac medical technology. Additionally, Picard Medical raised $17.4 million from its IPO, significantly improving its cash position to $11.5 million. The SynCardia TAH, the only total artificial heart approved by the FDA and Health Canada, has been implanted over 2,100 times, showcasing its potential in the heart transplant market.
These developments indicate a positive trajectory for Picard Medical, with a focus on expanding production and seeking FDA approval for new products, which could enhance its market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Picard Medical Reviews 2025 Financials and Future Outlook
- Significant Financial Growth: In 2025, the company achieved total revenue of $4.9 million, a 12.5% increase, with product revenue constituting 96%, indicating sustained market demand in cardiac medical technology and boosting investor confidence.
- Capital Structure Optimization: The company raised $17.4 million in net proceeds from its IPO and ended 2025 with $11.5 million in cash, a substantial increase from $0.1 million at the end of 2024, reflecting significant progress in financial management.
- Product Innovation Progress: The SynCardia TAH, the only total artificial heart approved by both the FDA and Health Canada, has been implanted over 2,100 times across 27 countries, demonstrating its widespread application potential in the heart transplant field to meet growing patient needs.
- Future Development Strategy: The company aims to achieve profitability by expanding production capacity, reducing per-unit costs, and improving gross margins, while actively seeking FDA approval for new products to broaden the eligible patient population and enhance market competitiveness.
See More
Picard Medical Reports Q1 Net Loss of $7.6M with 85% Revenue Growth
- Financial Performance: Picard Medical reported a net loss of $7.6 million in Q1, despite achieving an 85% year-over-year revenue growth to $1.2 million, indicating potential in market expansion but raising concerns about the impact of ongoing losses on future financing.
- Revenue Growth: The company's revenue increased from $650,000 in the same quarter last year to $1.2 million, reflecting a significant rise in product demand; however, persistent losses may affect investor confidence and stock performance.
- Market Outlook: Despite the losses, Picard Medical's revenue growth suggests enhanced competitiveness in the medical market, and effective cost control could improve financial health and attract further investment in the future.
- Historical Data Comparison: Compared to historical financial data, the current revenue growth rate indicates progress in product development and marketing efforts, yet ongoing losses require management's attention to ensure sustainable growth.
See More
Picard Medical Reports Q1 Revenue of $1.1M Driven by Increased STAH Utilization
- Revenue Growth: Picard Medical reported Q1 revenue of $1.1 million, reflecting a significant increase compared to the previous year, indicating rising demand for heart medical devices in the market.
- Increased Utilization: The higher utilization of the SynCardia Total Artificial Heart directly contributed to revenue growth, showcasing the company's technological advantage and market acceptance in cardiac treatment.
- Rental Income Boost: The increase in driver rental income further strengthened the company's financial performance, indicating growing customer reliance on its devices and laying a foundation for future revenue growth.
- Positive Market Outlook: With the rising number of heart disease patients, demand for Picard Medical's products is expected to continue growing, and the company's strategic positioning in the cardiac medical field will further solidify its market presence.
See More
Picard Medical Participates in ISHLT 2026 Annual Meeting
- Conference Participation: Picard Medical will showcase its latest fully implantable artificial heart technology at the ISHLT 2026 Annual Meeting on April 24, 2026, highlighting the company's ongoing innovation in treating heart and lung diseases.
- Technology Presentation: Andre R. Simon, Vice President of Clinical Affairs at SynCardia, will present a poster on the 'Emperor Total Artificial Heart,' emphasizing the development progress of the next-generation fully implantable heart platform, which is expected to attract significant attention from clinical experts.
- Industry Impact: Participation in the conference not only demonstrates Picard Medical's engagement with the global clinical community but also underscores the company's commitment to advancing innovation in mechanical circulatory support through scientific exchange and collaboration, potentially enhancing its market position.
- Global Network: SynCardia's artificial heart technology has been implanted over 2,100 times across 27 countries, making it the most widely used and extensively studied artificial heart globally, further solidifying its leadership in the heart disease treatment market.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, concerning securities purchased between September 2, 2025, and October 31, 2025.
- False Statement Allegations: The complaint alleges that Picard made false and misleading statements to the market, engaging in a manipulation scheme to fraudulently inflate its share price, resulting in investor losses when the truth emerged.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before April 13, 2026, to participate in the lawsuit and seek compensation, noting that the class has not yet been certified, leaving investors unrepresented until then.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to discuss their rights and understand the steps to participate in the lawsuit via phone or email.
See More
Faruqi & Faruqi Encourages Picard Medical Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Picard Medical, particularly for investors who purchased securities between September 2, 2025, and October 31, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Contact Information: Partner Josh Wilson encourages affected investors to reach out directly at 877-247-4292 or 212-983-9330 (Ext. 1310), providing a clear legal consultation channel to help investors understand their rights.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 13, 2026, emphasizing the importance of timely action to safeguard investor legal rights.
- Role of Securities Law Firm: As a leading national securities law firm, Faruqi & Faruqi's investigation indicates potential legal risks for Picard Medical, urging investors to stay informed about the situation to assess potential losses and legal options.
See More
Picard Medical Reviews 2025 Financials and Future Outlook
- Significant Financial Growth: In 2025, the company achieved total revenue of $4.9 million, a 12.5% increase, with product revenue constituting 96%, indicating sustained market demand in cardiac medical technology and boosting investor confidence.
- Capital Structure Optimization: The company raised $17.4 million in net proceeds from its IPO and ended 2025 with $11.5 million in cash, a substantial increase from $0.1 million at the end of 2024, reflecting significant progress in financial management.
- Product Innovation Progress: The SynCardia TAH, the only total artificial heart approved by both the FDA and Health Canada, has been implanted over 2,100 times across 27 countries, demonstrating its widespread application potential in the heart transplant field to meet growing patient needs.
- Future Development Strategy: The company aims to achieve profitability by expanding production capacity, reducing per-unit costs, and improving gross margins, while actively seeking FDA approval for new products to broaden the eligible patient population and enhance market competitiveness.
See More
Picard Medical Reports Q1 Net Loss of $7.6M with 85% Revenue Growth
- Financial Performance: Picard Medical reported a net loss of $7.6 million in Q1, despite achieving an 85% year-over-year revenue growth to $1.2 million, indicating potential in market expansion but raising concerns about the impact of ongoing losses on future financing.
- Revenue Growth: The company's revenue increased from $650,000 in the same quarter last year to $1.2 million, reflecting a significant rise in product demand; however, persistent losses may affect investor confidence and stock performance.
- Market Outlook: Despite the losses, Picard Medical's revenue growth suggests enhanced competitiveness in the medical market, and effective cost control could improve financial health and attract further investment in the future.
- Historical Data Comparison: Compared to historical financial data, the current revenue growth rate indicates progress in product development and marketing efforts, yet ongoing losses require management's attention to ensure sustainable growth.
See More
Picard Medical Reports Q1 Revenue of $1.1M Driven by Increased STAH Utilization
- Revenue Growth: Picard Medical reported Q1 revenue of $1.1 million, reflecting a significant increase compared to the previous year, indicating rising demand for heart medical devices in the market.
- Increased Utilization: The higher utilization of the SynCardia Total Artificial Heart directly contributed to revenue growth, showcasing the company's technological advantage and market acceptance in cardiac treatment.
- Rental Income Boost: The increase in driver rental income further strengthened the company's financial performance, indicating growing customer reliance on its devices and laying a foundation for future revenue growth.
- Positive Market Outlook: With the rising number of heart disease patients, demand for Picard Medical's products is expected to continue growing, and the company's strategic positioning in the cardiac medical field will further solidify its market presence.
See More
Picard Medical Participates in ISHLT 2026 Annual Meeting
- Conference Participation: Picard Medical will showcase its latest fully implantable artificial heart technology at the ISHLT 2026 Annual Meeting on April 24, 2026, highlighting the company's ongoing innovation in treating heart and lung diseases.
- Technology Presentation: Andre R. Simon, Vice President of Clinical Affairs at SynCardia, will present a poster on the 'Emperor Total Artificial Heart,' emphasizing the development progress of the next-generation fully implantable heart platform, which is expected to attract significant attention from clinical experts.
- Industry Impact: Participation in the conference not only demonstrates Picard Medical's engagement with the global clinical community but also underscores the company's commitment to advancing innovation in mechanical circulatory support through scientific exchange and collaboration, potentially enhancing its market position.
- Global Network: SynCardia's artificial heart technology has been implanted over 2,100 times across 27 countries, making it the most widely used and extensively studied artificial heart globally, further solidifying its leadership in the heart disease treatment market.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, concerning securities purchased between September 2, 2025, and October 31, 2025.
- False Statement Allegations: The complaint alleges that Picard made false and misleading statements to the market, engaging in a manipulation scheme to fraudulently inflate its share price, resulting in investor losses when the truth emerged.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before April 13, 2026, to participate in the lawsuit and seek compensation, noting that the class has not yet been certified, leaving investors unrepresented until then.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to discuss their rights and understand the steps to participate in the lawsuit via phone or email.
See More
Faruqi & Faruqi Encourages Picard Medical Investors to Reach Out
- Legal Investigation Initiated: Faruq & Faruqi, LLP is investigating potential claims against Picard Medical, particularly for investors who purchased securities between September 2, 2025, and October 31, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Contact Information: Partner Josh Wilson encourages affected investors to reach out directly at 877-247-4292 or 212-983-9330 (Ext. 1310), providing a clear legal consultation channel to help investors understand their rights.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical is April 13, 2026, emphasizing the importance of timely action to safeguard investor legal rights.
- Role of Securities Law Firm: As a leading national securities law firm, Faruqi & Faruqi's investigation indicates potential legal risks for Picard Medical, urging investors to stay informed about the situation to assess potential losses and legal options.
See More
